Email Us Here

Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer

Eleison Pharmaceuticals has announced it has passed the halfway point for enrollment in the first stage of its ongoing Phase II study of ILC (Inhaled Lipid-complexed Cisplatin).